['The study was performed to assess the safety of strontium ranelate in accordance with the ICH, E14 guidelines for QT/QT(c) studies. Its primary objective was to compare supratherapeutic repeated dosing of strontium ranelate (4\u2003g\u2003day⁻¹ for 15\u2003days) with placebo on the largest time-matched mean QT(c) variation, from baseline to under treatment values, in healthy subjects.', 'Ninety-six healthy male and female subjects (27.7 ± 7.5\u2003years) were included to receive 1\u2003day of placebo followed by 15\u2003days of supratherapeutic repeated dosing of strontium ranelate (4\u2003g\u2003day⁻¹), in a 4\u2003month, randomized, placebo (16\u2003days) and positive-controlled (single dose of moxifloxacin 400\u2003mg preceded by 15\u2003days of placebo), double-blind, double dummy, crossover design. Measurement of QT interval was performed automatically on the ECGs with subsequent manual onscreen over-reading by cardiologists using electronic callipers.', 'The largest time-matched difference in QT(c) I (individual QT correction for heart rate) between moxifloxacin 400\u2003mg and placebo was observed at 2\u2003h post dose (mean [95% CI] 10.62 [7.90, 13.35] ms). For strontium ranelate (4\u2003g\u2003day⁻¹) the largest time-matched difference in QT(c) I compared with placebo was observed at 1\u2003h post dose (mean [90% CI] 7.54 [5.17, 9.90] ms). No subject had a QT(c) greater than 480\u2003ms during the study. Both moxifloxacin and strontium ranelate were well tolerated in healthy subjects.'] Does repeated supratherapeutic dosing of strontium ranelate over 15 days prolong QT ( c ) interval in healthy volunteers?